<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01331486</url>
  </required_header>
  <id_info>
    <org_study_id>09-2279</org_study_id>
    <nct_id>NCT01331486</nct_id>
  </id_info>
  <brief_title>Nitric Oxide Mediated Vasodilatory Response to Hawthorn Standardized Extract</brief_title>
  <official_title>Nitric Oxide Mediated Vasodilatory Response to Hawthorn Standardized Extract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prehypertension and mild hypertension affect an estimated 157 million U.S. adults.&#xD;
      Cardiovascular disease (CVD) risk and associated mortality is elevated in this population.&#xD;
      Treatment options are limited consisting of lifestyle modification, which is often&#xD;
      ineffective, or drug therapy, which carries risk of side effects. Highly safe, efficacious,&#xD;
      and acceptable treatment options for this population are needed. Hawthorn standardized&#xD;
      extract (HSE) is approved for use in Europe to treat heart failure, and preliminary evidence&#xD;
      suggests it may have a blood pressure lowering effect. However, prior trials of hawthorn have&#xD;
      based dosage recommendations on animal studies. Therefore, the investigators propose a&#xD;
      dose-finding study to measure the pharmacodynamic effect of three doses of standardized&#xD;
      hawthorn extract and placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FMD Max</measure>
    <time_frame>7d</time_frame>
    <description>Brachial artery flow mediated dilation max (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BP</measure>
    <time_frame>7d</time_frame>
    <description>Blood pressure</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Prehypertension</condition>
  <condition>Mild Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hawthorn</intervention_name>
    <description>Hawthorn standardized extract liquid capsule</description>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_label>Mid dose</arm_group_label>
    <other_name>Gaia Hawthorn Supreme</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>Matched placebo liquid capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Recent ambulatory daytime systolic BP average between 120 - 155 mmHg or diastolic BP&#xD;
             between 80-95 mmHg&#xD;
&#xD;
          2. Age 18 years and older.&#xD;
&#xD;
          3. Ability to speak English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any antihypertensive medication use (ACE inhibitors, ARB, beta-blockers, calcium&#xD;
             channel blockers, diuretics, alpha agonists or antagonists, nitrates, direct&#xD;
             vasodilators such as hydralazine, aldosterone antagonists, direct renin inhibitors,&#xD;
             endothelin antagonists)&#xD;
&#xD;
          2. Current tobacco use.&#xD;
&#xD;
          3. Diagnosed with diabetes, known coronary artery disease, severe aortic stenosis,&#xD;
             idiopathic hypertrophic subaortic stenosis (IHSS), or upper extremity vascular&#xD;
             obstruction.&#xD;
&#xD;
          4. Pregnancy or breast feeding.&#xD;
&#xD;
          5. Using estrogen-containing birth control methods.&#xD;
&#xD;
          6. Unwillingness to forgo vitamins C and E, fish oil, niacin, arginine, OTC&#xD;
             decongestants, and NSAIDs such as advil, motrin, and nuprin during the study period.&#xD;
&#xD;
          7. Unwillingness to forgo use of phosphodiesterase inhibitors (sildenafil - 36 hours,&#xD;
             vardenafil - 36 hours, tadalafil - 96 hours) prior to study visits.&#xD;
&#xD;
          8. Unwillingness to refrain from vigorous exercise on the morning of study visits.&#xD;
&#xD;
          9. Women with childbearing potential who do not agree to practice effective birth control&#xD;
             (condom, diaphragm, cervical cap, copper IUD, abstinence).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary N Asher, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNC Department of Family Medicine</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Asher GN, Viera AJ, Weaver MA, Dominik R, Caughey M, Hinderliter AL. Effect of hawthorn standardized extract on flow mediated dilation in prehypertensive and mildly hypertensive adults: a randomized, controlled cross-over trial. BMC Complement Altern Med. 2012 Mar 29;12:26. doi: 10.1186/1472-6882-12-26.</citation>
    <PMID>22458601</PMID>
  </results_reference>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>April 6, 2011</study_first_submitted>
  <study_first_submitted_qc>April 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2011</study_first_posted>
  <last_update_submitted>February 6, 2013</last_update_submitted>
  <last_update_submitted_qc>February 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prehypertension</keyword>
  <keyword>Mild hypertension</keyword>
  <keyword>Flow mediated dilation</keyword>
  <keyword>Hawthorn</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Prehypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

